POTEB2: A Drug Target / Disease Biomarker (G100287399)

Target Name: POTEB2

NCBI ID: G100287399

POTEB2: A Drug Target / Disease Biomarker

POTassium channel modulators, also known as P-type voltage-gated channels, are a family of proteins that play a crucial role in many physiological processes in the body. One of the best-known P-type voltage-gated channels is POTassium channel modulator (Ptm), which is a drug target and a biomarker for various diseases, including heart failure, atrial fibrillation, and neurodegenerative diseases.

Ptm is a P-type voltage-gated channel that is expressed in many different tissues and cells in the body. It is a key channel for the regulation of various physiological processes, including muscle and nerve function, as well as heart rhythm and blood pressure. Ptm has four different isoforms, which are different in their trafficking, localization, and function.

The most abundant isoform of Ptm is the N-type voltage-gated channel, which is responsible for generating action potentials in muscle and nerve fibers. This isoform is expressed in the muscle and nerve fibers and is involved in the regulation of muscle and nerve contractions.

The second-most abundant isoform of Ptm is the P-type voltage-gated channel, which is responsible for the regulation of heart rhythm. This isoform is expressed in the cardiac muscle and is involved in the regulation of heart rate and contractions.

The third isoform of Ptm is the R-type voltage-gated channel, which is responsible for the regulation of blood pressure. This isoform is expressed in the smooth muscle of the blood vessels and is involved in the regulation of blood vessel diameter and blood pressure.

The fourth and last isoform of Ptm is the T-type voltage-gated channel, which is also responsible for the regulation of blood pressure. This isoform is expressed in the heart and is involved in the regulation of heart rate and contractions.

Ptm is a drug target for various diseases, including heart failure, atrial fibrillation, and neurodegenerative diseases. Heart failure is a condition in which the heart is not able to pump enough blood to meet the body's needs. Ptm has been shown to be involved in the regulation of heart failure, and studies have shown that blocking Ptm can improve heart function in patients with heart failure.

Atrial fibrillation is a type of irregular heart rhythm that can lead to palpitations, shortness of breath, and dizziness. Ptm is also involved in the regulation of atrial fibrillation, and studies have shown that blocking Ptm can improve the heart rate and reduce the risk of stroke in patients with atrial fibrillation.

Neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, are a group of progressive neurological disorders that are characterized by the progressive loss of brain cells. Ptm is also involved in the regulation of neurodegenerative diseases, and studies have shown that blocking Ptm can improve neurodegenerative symptoms such as tremors and rigidity.

Ptm is also a biomarker for various diseases, including heart failure, atrial fibrillation, and neurodegenerative diseases. The levels of Ptm have been shown to be elevated in patients with heart failure, atrial fibrillation, and neurodegenerative diseases. This has led to the idea that Ptm may be a useful biomarker for these diseases.

In addition to its role as a drug target and biomarker, Ptm is also involved in the regulation of various physiological processes in the body. It plays a key role in the regulation of muscle and nerve function, as well as heart rhythm and blood pressure.

Ptm is involved in the regulation of muscle and nerve function by allowing the flow of calcium ions into the muscle fibers. This increase in calcium ions allows the muscle fibers to contract, which is necessary for muscle movement and function.

Ptm is also involved in the regulation of heart rhythm by controlling the

Protein Name: POTE Ankyrin Domain Family Member B2

More Common Targets